The once-daily Wegovy weight loss pill is now available for private purchase in UK pharmacies, offering a new treatment option for obesity.
Developed by Novo Nordisk, the medication contains semaglutide, the same active ingredient as the Wegovy injection. Unlike the injectable form, this oral version requires daily dosing rather than weekly injections.
Clinical trials have shown Wegovy to be effective in promoting significant weight loss when combined with diet and exercise. In a 68-week study, participants using Wegovy lost an average of 15% of their body weight compared to 2.4% in the placebo group.
Dr. Emily Carter, an obesity specialist at St. Thomas' Hospital, noted, "This oral formulation provides greater accessibility for patients who prefer not to use injections, though adherence to daily dosing remains crucial for effectiveness."
The availability of Wegovy in pill form expands treatment options for the UK's growing obesity crisis, with Public Health England reporting that over 28% of adults are obese.
Health experts caution that Wegovy should only be used under medical supervision due to potential side effects including nausea, diarrhea, and increased heart rate.
Wegovy weight loss pill mechanism explained
Wegovy works by mimicking a hormone called GLP-1, which regulates appetite and food intake. By activating GLP-1 receptors in the brain, the medication reduces hunger and increases feelings of fullness.
The oral formulation uses a special delivery system to protect semaglutide from stomach acids, allowing it to reach the intestines where it can be absorbed. This technology enables the drug to maintain its effectiveness despite daily dosing.
While Wegovy is not a standalone solution, it represents a significant advancement in pharmacological obesity treatment. Patients are advised to combine the medication with lifestyle changes for optimal results.
Novo Nordisk has not yet announced pricing for the oral Wegovy, but estimates suggest it could cost between £200-£300 per month, significantly less than the injectable version.
Regulatory approval for the oral Wegovy is expected by late 2026, with NHS availability likely to follow after initial private market testing.
Patients considering Wegovy should consult their GP to determine if the medication is appropriate for their individual health needs and weight loss goals.
Key questions
- Is Wegovy available on the NHS?
- Currently, Wegovy is only available for private purchase in UK pharmacies. NHS availability is expected to begin in late 2026 following regulatory approval and cost-effectiveness assessments.
- How effective is Wegovy for weight loss?
- Clinical trials show Wegovy can lead to an average of 15% body weight reduction over 68 weeks when combined with diet and exercise, significantly more than placebo groups.
